Advanced Rectal Cancer Clinical Trial
Official title:
Radiotherapy Followed by Chemotherapy With Target Therapy and Anti-PD-1 Immunotherapy in Locally Advanced Rectal Cancer With Refractory Liver Metastasis/Pulmonary Metastasis(Miracle-2): A Prospective, Single Arm, Multi-Center, Phase II Clinical Trial
Though surgical resection remains the primary choice for advanced rectal cancer, about 80% are considered unresectable due to the number, size, or location of metastases. The overall prognosis of patients who accepted traditional treatment methods is still poor. Therefore, the investigators designed a combination therapy, short-course radiotherapy followed by chemotherapy with target therapy and anti-PD-1 immunotherapy. This study implement the combination therapy in patients with rectal cancer who are initially unresectable in the locally advanced stage with multiple liver/pulmonary metastases, to evaluate whether they can improve the objective response rate, the conversion rate of radical surgery and prolong the overall survival of patients, and strive to provide high-level medical evidence for the clinical treatment.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03156036 -
Preoperative CRT With Capecitabine ± Temozolomide in Patients With LARC
|
Phase 2 | |
| Active, not recruiting |
NCT03781323 -
Neoadjuvant FOLFOX Therapy With Short Course Radiation and Active Surveillance in Locally Advanced Rectal Cancer
|
Phase 2 | |
| Recruiting |
NCT05228431 -
Modified Sandwich Therapeutic Regimen for Locally Advanced Rectal Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT02031939 -
Randomized Controlled Study on Optimize Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer
|
Phase 3 | |
| Not yet recruiting |
NCT05359393 -
A Combination Therapy Including Anti-PD-1 Immunotherapy in MSS Rectal Cancer With Resectable Distal Metastasis
|
Phase 2 | |
| Suspended |
NCT01872104 -
Safety and Efficiency of Photodynamic Therapy for Rectal Cancer
|
Phase 2/Phase 3 |